MedPath

Success in Comaneci-assist Coils Embolization Surveillance Study (SUCCESS)

Completed
Conditions
Intracranial Aneurysm
Registration Number
NCT04518670
Lead Sponsor
Rapid Medical
Brief Summary

The Comaneci Embolization Assist Device is indicated for use in the neurovasculature as a temporary endovascular device used to assist in the coil embolization of wide-necked intracranial aneurysms with a neck width ≤ 10 mm. A wide-necked intracranial aneurysm (IA) defines the neck width as ≥ 4 mm or a dome-to-neck ratio \< 2.

The objective of the Postmarket Surveillance Plan is to assess safety and performance as used in postmarket clinical practice in the U.S.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
90
Inclusion Criteria
  1. Patient has a documented intracranial ruptured or unruptured aneurysm, suitable for embolization by coils.
  2. Patient is considered for treatment with coil embolization assisted by the Comaneci Device for wide-necked intracranial aneurysms with neck width ≤ 10 mm. A wide-necked intracranial aneurysm is defined by the neck width as ≥ 4 mm or a dome-to-neck ratio < 2.
  3. A signed informed consent by the patient or legally authorized representative
Exclusion Criteria
  1. Patient with known hypersensitivity to nickel-titanium

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Periprocedural events24 Hours post procedure

Rates of all adverse events occurring within 24 hours post-procedure and hospital discharge status.

Adverse events30 days post procedure

All adverse events at discharge and up to 30 days post procedure.

Functional status30 days post procedure

Functional status at discharge and 30 days assessed using the modified Rankin Scale (mRS).

using the modified Rankin Scale (mRS). This scale runs from 0-6, from no symptoms to death as follows:

* 0 - No symptoms

* 1 - No significant disability. Able to carry out all usual activities, despite some symptoms.

* 2 - Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.

* 3 - Moderate disability. Requires some help, but able to walk unassisted.

* 4 - Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.

* 5 - Severe disability. Requires constant nursing care and attention, bedridden, incontinent.

* 6 - Dead.

Successful intracranial aneurysm (IA) occlusion6 Months Post procedure

Successful intracranial aneurysm (IA) occlusion, that is a stable IA occlusion, measured by Raymond Roy classification I or II taken at 6 months (± 21d) post procedure without the need for re-treatment of the target IA, using DSA.

Good clinical outcome6 Months Post procedure

Good clinical outcome- mRS shift @ 6 months (change @ 6 months from pre procedure) and tetrachotomized (0,1, 2, 3-6) mRS analysis

Successful intracranial aneurysm occlusionend of procedure

Successful intracranial aneurysm occlusion (measured by Raymond Roy classification I or II) at the end of procedure, using digital subtraction angiography (DSA).

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (8)

USA Health University Hospital

🇺🇸

Mobile, Alabama, United States

Santa Barbara Cottage

🇺🇸

Santa Barbara, California, United States

University of Buffalo

🇺🇸

Buffalo, New York, United States

Baptist Health Research Institute

🇺🇸

Jacksonville, Florida, United States

Carondelet St. Joseph's Hospital (Tenet)

🇺🇸

Tucson, Arizona, United States

St. Mary's Medical Ctr (Tenet)

🇺🇸

West Palm Beach, Florida, United States

Los Robles

🇺🇸

Thousand Oaks, California, United States

Texas Stroke Institute (Sarah Cannon TN)

🇺🇸

Dallas, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath